Wendtner, Clemens M., Hallek, Michael, Fraser, Graeme A. M., Michallet, Anne-Sophie, Hillmen, Peter, Durig, Jan, Kalaycio, Matt, Gribben, John G., Stilgenbauer, Stephan, Buhler, Andreas, Kipps, Thomas J., Purse, Brendan, Zhang, Jennie, De Bedout, Sabine, Mei, Jay and Chanan-Khan, Asher (2016). Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*. Leuk. Lymphoma, 57 (6). S. 1291 - 1300. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Full text not available from this repository.

Abstract

The objective of this study was to evaluate the safety and efficacy of different lenalidomide starting doses in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). CLL patients were randomized to receive lenalidomide at initial doses of 5, 10, or 15mg/d (N=103). Doses were escalated by 5mg every 28-d up to a maximum of 25mg/d; dose reductions in up to 5mg decrements were permitted. The most common grade3 adverse events (AEs) were neutropenia and thrombocytopenia. Ten patients died during therapy (four deaths considered as related to lenalidomide); 12 patients experienced second primary malignancies. The most common cause for treatment discontinuation was AEs. Overall response rates were similar across arms. Progression-free survival and overall survival rates were longer in patients who escalated treatment (to 15 or 20mg/d) versus those who did not. Lower starting doses allowed subsequent dose escalation of lenalidomide while maintaining an acceptable tolerability profile in patients with relapsed/refractory CLL.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Wendtner, Clemens M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hallek, MichaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fraser, Graeme A. M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Michallet, Anne-SophieUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hillmen, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Durig, JanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kalaycio, MattUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gribben, John G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stilgenbauer, StephanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Buhler, AndreasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kipps, Thomas J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Purse, BrendanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Zhang, JennieUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
De Bedout, SabineUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mei, JayUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Chanan-Khan, AsherUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-275059
DOI: 10.3109/10428194.2015.1128540
Journal or Publication Title: Leuk. Lymphoma
Volume: 57
Number: 6
Page Range: S. 1291 - 1300
Date: 2016
Publisher: TAYLOR & FRANCIS LTD
Place of Publication: ABINGDON
ISSN: 1029-2403
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
SALVAGE THERAPY; CLL CELLS; RITUXIMAB; FLUDARABINE; BENDAMUSTINE; IDELALISIBMultiple languages
Oncology; HematologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/27505

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item